IP Library Granted Patent US 9,175,060
Granted Patent B2
US 9,175,060 · App. 12/514,790 · Granted Nov 3, 2015

PEG modified exendin or exendin analog and compositions and use thereof

Inventors: Wenchao Bao (Shanghai, CN); Hongjing Xu (Shanghai, CN); Gang Yu (Shanghai, CN); Yajun Zuo (Shanghai, CN)
Assignee: Shanghai Benemae Pharmaceutical Corporation
C07K14/57563A61K38/26A61K47/48215A61K47/48338A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,175,060
App. No.
12/514,790
Granted
Nov 3, 2015
Kind
B2
Abstract

Exendins or exendin analogs modified by one or more PEG derivatives that may be linked to one or more amino acids of the exendins or exendin analogs are provided. The PEG derivatives may have branched structure set forth in any one of formulas I-IV. Compositions including the PEG derivative modified exendin or exendin analog, methods of making or administering the modified exendin or exendin analog, and various uses thereof are also provided.

Claims (12)

1. A PEG modified exendin or exendin analog comprising one or more PEG derivatives linked to one or more amino acids of said exendin or exendin analog, wherein the molecular weight of said one or more PEG derivatives exceeds 20,000 Da, and said one or more PEG derivatives comprise a branched structure set forth in Formula IV below:

wherein PEG is —O(CH 2 CH 2 O) q , q is a positive integer, and Me is a methyl group.

2. The PEG modified exendin or exendin analog of claim 1 , wherein the exendin or exendin analog comprises the amino acid sequence set forth in SEQ ID NO: 1.

3. The PEG modified exendin or exendin analog of claim 1 , wherein the exendin or exendin analog comprises the amino acid sequence set forth in SEQ ID NO: 2.

4. The PEG modified exendin or exendin analog of claim 1 , wherein the exendin or exendin analog comprises one or more amino acid sequences set forth in SEQ ID NO: 3 to NO: 229.

5. The PEG modified exendin or exendin analog of claim 1 , wherein the exendin or exendin analog comprises one or more amino acid sequences set forth in SEQ ID NO: 230 to NO: 265.

6. The PEG modified exendin or exendin analog of claim 1 , wherein said one or more PEG derivatives have a molecular weight in the range of above 20,000 Da to about 50,000 Da.

7. The PEG modified exendin or exendin analog of claim 1 , wherein said one or more PEG derivatives are activated to link to said exendin or exendin analog by N-Hydroxysuccinimide.

8. The PEG modified exendin or exendin analog of claim 1 comprising one, two, three or four branched PEG derivatives.

9. The PEG modified exendin or exendin analog of claim 8 comprising one branched PEG derivative.

10. A composition comprising a PEG modified exendin or exendin analog of claim 1 .

11. A method of treating diabetes mellitus comprising administering a PEG modified exendin or exendin analog of claim 1 to a subject.

Assignments (3)
CHANGE OF NAME Recorded Feb 10, 2015
From: SHANGHAI HUAYI BIO-LAB CO., LTD.
To: SHANGHAI BENEMAE PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 034933/0940 →
CHANGE OF NAME AND ADDRESS Recorded Feb 10, 2015
From: SHANGHAI BENEMAE PHARMACEUTICAL COMPANY LIMITED
To: SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION
Reel/Frame 034934/0060 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2009
From: BAO, WENCHAO; XU, HONGJING; YU, GANG; ZUO, YAJUN
To: SHANGHAI HUAYI BIO-LAB CO., LTD.
Reel/Frame 022681/0660 →
Priority Claims (2)
CN 2006 1 0118326 · Nov 14, 2006 · national
CN 2007 1 0138718 · Jul 23, 2007 · national
Continuity (1)
Related Publication 20100240586A1 · Sep 23, 2010